Objectives: This study evaluates the diagnostic value of poorly relaxed external sphincter (PRES) in men with voiding dysfunction. We analyzed clinical and video-urodynamic characteristics to identify predictive factors of PRES in patients with lower urinary tract symptoms (LUTS) refractory to α-1 adrenoceptor blocker (α-blocker) therapy.
| INTRODUCTION
Lower urinary tract symptoms (LUTS) are bothersome symptoms that increase with age in both men and women, 1 and approximately 20%
of middle aged-elderly men have LUTS severe enough to interfere with quality of life. 2 LUTS are composed of both voiding and storage symptoms. The voiding symptoms predominate in men compared with women, especially in elderly patients. This predominance is due to the high prevalence of benign prostate hyperplasia (BPH) in aging men. 3 Perfect bladder voiding (emptying) requires a sustained contraction of the bladder detrusor muscle, a concomitant lowering of resistance of the smooth and striated urethral sphincter, and the absence of an anatomical obstruction. BPH remains an important cause of voiding dysfunction in men. Nonetheless, voiding dysfunction may also be secondary to other causes, such as poor relaxation of the external sphincter (PRES), bladder neck dysfunction (BND), or urethral stricture. 4 In men with voiding dysfunction, PRES and BND are less common compared with BPH with obstruction (BPO). For patients, however, in whom the first-line medication for BPO, such as α-1 adrenoceptor blocker (α-blocker) has failed, the ratio of PRES and BND increases. In our previous study using video-urodynamic characteristics to make a definitive diagnosis of voiding dysfunction in men who failed to obtain relief from α-blocker treatment, BPO, BND, and PRES accounted for 45.6%, 37.1%, and 17.3% of the total diagnoses, respectively. 4 This suggests that both BND and PRES play important roles in men with voiding dysfunction refractory to α-blocker treatment. Although the clinical symptoms of BPO, BND, and PRES are similar, the treatment of these three bladder outlet disorders differs. The present study analyzed clinical and video-urodynamic characteristics to identify predictive factors of PRES in men with LUTS refractory to α-blocker therapy. We also sought a simple method other than urodynamic studies to screen for PRES in men with voiding dysfunction who have failed to obtain relief with α-blocker treatment.
| METHODS
All consecutive male patients with LUTS refractory to α-blocker treatment for at least 1 month in a single tertiary medical center between 1997 and 2013 were included in this study. A total of 3379 patients were enrolled. The present study also included 930 patients with LUTS who had failure of α-1 blocker treatment from our previously published study on bladder neck and external sphincter dysfunction. 4 We retrospectively reviewed the medical charts and videourodynamic study reports of all patients. The study was approved by the Ethics Committee of the Tzu Chi General Hospital (IRB:
104-15-B). The committee waived informed consent due to the retrospective nature of the study.
All patients underwent video-urodynamic studies for a definitive diagnosis after medical treatment failure. Medical failure of α-blocker treatment was defined as subjective perception of no significant clinical improvement in LUTS based on the International Prostate Symptom Score (IPSS) and quality of life index after α-1 adrenoceptor blocker treatment (such as tamsulosin 0.4 mg daily, silodosin 4 mg twice daily, or doxazosin 4 mg daily) for at least 1 month.
Patients with previous lower urinary tract surgery, neurogenic disease such as stroke, Parkinson's disease, spinal cord injury, dementia, acute or chronic urinary retention, or urolithiasis were excluded.
Patients with prostate-specific antigen >4 ng/mL were scheduled for Video-urodynamic studies were performed according to the recommendations of the International Continence Society. 5 The details of the video-urodynamic studies are well described and reported in a previous study. 6 The video-urodynamic study was repeated at least twice to obtain reproducible pressure-flow tracings. BPO, PRES, BND, urethral sphincter pseudodyssynergia, increased bladder sensation, DO, detrusor underactivity, and DO with inadequate contractility were diagnosed according to the findings of characteristic bladder or bladder outlet dysfunction during the testing. [5] [6] [7] Bladder outlet obstruction (BOO) was defined as P det.Qmax ≥ 50 cm H 2 O or AG number ≥ 40 on pressure-flow study. In patients with equivocal pressure-flow results, bladder outlet dysfunction was diagnosed based on the features of the bladder neck, prostatic urethra, and external sphincter during voiding cystourethrography. 5 BPO and BND were diagnosed if the narrow segment during the voiding phase was in the prostatic urethra and bladder neck, respectively. 6,7 PRES was diagnosed if the urethral sphincter electromyography (EMG)
showed no relaxation of a narrow membranous urethra during voiding. 8 After the video-urodynamic studies, patients with LUTS were divided into voiding dysfunction and bladder dysfunction subgroups.
The patients with voiding dysfunction were further subdivided into BPO, BND, US, and PRES subgroups according to video-urodynamic characteristics, which were analyzed.
Univariate and multivariate analyses of the patient demographic and video-urodynamic characteristics were performed for patients with PRES and BOO. We constructed a simple scale consisting of the three most predictive clinical parameters of PRES. The purpose of the scale was to screen for PRES in men with LUTS in an office-based setting. Each parameter was given a score of 0 or 1 based on the clinical parameters, with a total score 0 to 3, for which a higher score indicates a higher probability of PRES. The most appropriate cut-off was then examined for the best predictive ability.
| Statistical analysis
Continuous variables are presented as mean ± SD, and categorical data are presented as numbers and percentages (%).
Comparisons between the groups were tested using independent sample-T test for univariate analysis and linear regression for multivariate analysis. Significance was set at P < 0.05. Statistical analysis was performed using SPSS 15.0 (SPSS, Chicago, IL, USA).
| RESULTS
Of the 3379 men included in the study who completed the videourodynamic studies, 2078 were diagnosed with voiding dysfunction based on video-urodynamic studies. smaller CBC (351 ± 137 vs 526 ± 151 mL, P < 0.001) and lower Qmax (9.54 ± 4.77 vs 19.3 ± 4.24 mL/s, P < 0.001) compared with the normal group. We chose the three parameters that had the largest area under the receiver operating characteristic (ROC) curve (AUC) and which were easy to obtain, as the predictors of PRES. points, the sensitivity and specificity of predicting PRES were 32.0%
and 92.4% respectively. The sensitivity and specificity increased to 52.8% and 87.1%, respectively with a cut-off point = 3.
| DISCUSSION
In the present study, BPO remained the most common cause of voiding dysfunction in middle aged-elderly men with LUTS. Moreover, the prevalence of BND and PRES is increased in the α-blocker-refractory group. Because the management of these three conditions differs, screening men based on clinical urological examinations or videourodynamic study is necessary. α-Blocker treatment had an excellent effect in patients with voiding dysfunction due to BPO and BND. The same therapeutic effect was not observed, however, in patients with PRES. Gajewski et al con-
cluded that α-blockers do not influence the pudendal nervedependent urethral response in the cat through peripheral action. 9 Chancellor et al reported that terazosin, a selective α-1 adrenoceptor blocker, had little or no effect on the striated sphincter function in spinal cord injured (SCI) patients and had no effect on functional obstruction caused by external sphincter dyssynergia in these patients. In this study, among men with voiding dysfunction after α-blocker treatment, those with PRES had a significantly smaller total prostate volume and a more stable bladder (higher bladder volume at FSF, larger bladder capacity, and lower incidence of DO) compared with patients with BOO caused by other anatomical etiologies such as BND or BPO.
It is well established that BOO not only causes voiding dysfunction but also results in DO and decreases bladder compliance. The The larger bladder capacity and more stable bladder in PRES may be explained by the interaction between the bladder detrusor and external sphincter. Contraction of the external urethral sphincter can result in suppression of the reflex detrusor contraction, which is suggested to be reflexive in nature and is known as the voluntary urinary inhibition reflex. 18 With regard to this mechanism, pelvic floor exercise has been proved to cause a decline in detrusor contraction and an increase in urethral pressure, suppressing the micturition reflex by repeated contraction of external sphincter striated muscle. 
| CONCLUSION
In this study, we established a simple scale to predict PRES in the office setting using clinical symptoms and examinations that can be done without invasive urodynamic studies. The scale is composed of three parameters: voided volume, TPV, and urgency/UUI symptoms.
The scoring system ranges from 0 to 3 points, with higher scores representing a higher probability of PRES. When a total ≥3 points was set as the cut-off, the sensitivity and specificity to predict PRES were 52.78% and 87.10%, respectively.
If a man has persistent LUTS after first-line α-blocker treatment, small TPV, large voided volume and no urgency/UUI symptoms, a diagnosis of PRES should be investigated. Urodynamic pressure-flow studies and video-urodynamic studies remain the most reliable diagnostic tools for making an accurate diagnosis of PRES. Nonetheless, for those in whom a urodynamic study is not indicated or available, this simple scale could provide an easy and quick way to determine whether male patients with voiding problems refractory to α-blocker treatment are likely to have voiding dysfunction due to PRES. Due to the high specificity of the scale, only those patients excluded from having PRES (e.g. those with a score of 0) may be considered for surgical treatment of BND or BPO without urodynamic confirmation. In patients for whom PRES cannot be excluded, further evaluation is necessary before any invasive procedure is undertaken. Thus, unnecessary or excessive medication or surgery and their potential complications can be avoided.
In men with voiding dysfunction in which the first-line α-blocker treatment failed to provide relief, BPO and BND should be considered. For those in whom medical treatment failed and who have a small TPV, high voided volume, and little or no urgency/UUI symptoms, PRES should be highly suspected. Surgical intervention in patients with suspected PRES should not be performed unless they are proven to have BOO.
